

Test Comparison Chart for Maternal Serum Screening and Diagnostic Testing

This summary chart should be read in conjunction with the full description of each test on MyTestingOptions.com.

	Screening*					Diagnostic	
	FirstScreen®	IntegratedScreen SM	SequentialScreen SM	SerumIntegratedScreen SM	Afp4®	Chorionic Villi Sampling (CVS)	Amniocentesis
Testing Period	10-13 weeks	Part 1: 10-13 weeks Part 2: 15-21 weeks	Part 1: 10-13 weeks Part 2: 15-21 weeks	Part 1: 10-13 weeks Part 2: 15-21 weeks	15-21 weeks	10-12 weeks	15-23 weeks
Risks of Testing	Non-invasive blood test. No harmful side effects to you or your baby.	Non-invasive blood test. No harmful side effects to you or your baby.	Non-invasive blood test. No harmful side effects to you or your baby.	Non-invasive blood test. No harmful side effects to you or your baby.	Non-invasive blood test. No harmful side effects to you or your baby.	Average risk for miscarriage 1 in 100. Prior to 9 weeks, increased risk for limb defects.	Risk for miscarriage 1 in 300 to 1 in 500. Prior to 15 weeks, increased risk for miscarriage, up to 1 in 100
Disease Detection (approximate)							
Down Syndrome	83%	92%	Part 1: 70% Part 2: 90%	87%	81%	99%	99%
Trisomy 18	80%	90%	Part 1: 80% Part 2: 90%	90%	80%	99%	99%
Open Neural Tube Defects (such as Anencephaly and Spina Bifida)	NA	80%	Part 2: 80%	80%	80%	NA	96%
Other Chromosome Abnormalities (such as trisomy 13)	NA	NA	NA	NA	NA	99%	99%
Inherited Diseases (when specific risks have been identified, such as Tay-Sachs disease and cystic fibrosis)	NA	NA	NA	NA	NA	Yes, when ordered by your doctor. Detection rate varies by disease tested for.	Yes, when ordered by your doctor. Detection rate varies by disease tested for.

*Detection rate estimates for Genzyme maternal serum screening tests are based on US and international studies.

Afp4® and FirstScreen® are registered service marks of Genzyme Corporation.

IntegratedScreenSM, SequentialScreenSM, and SerumIntegratedScreenSM are service marks of Genzyme Corporation.